Prevention of Incontinence-associated Dermatitis and Maintenance of Local Skin Microclimate

Inclusion Criteria:

1. Intensive care unit incontinent patients (incontinence time ≥2 days)

2. Age ≥18 years

3. patients at high risk of IAD (Perineal Assessment Tool ≥ 7)

4. Voluntarily participate in the study and sign an informed consent form. If thesubject is unable to read and sign the informed consent form due to incapacitationor other reasons, their guardian is required to represent the informed process andsign the informed consent form. If the subject is unable to read the informedconsent form (e.g., illiterate subjects), a witness will be required to witness theinformed process and sign the informed consent form.

Exclusion Criteria:

1. Patients who have developed IAD

2. Expected subsequent stay in the intensive care unit <5 days

3. Use of nappies, pull-ups, incontinence pads, etc.

4. Simple urinary incontinence with indwelling catheterization, external urinary bagwithout leakage; simple fecal incontinence with built-in drainage device, externalostomy bag, OB tampon without leakage; double incontinence with indwellingcatheterization, external urinary bag, built-in drainage device, external ostomybag, OB tampon without leakage.

5. The IAD may affect the skin area within the scope of the disease that affects theIAD judgment.

6. The IAD may affect the skin area within the scope of the skin breaks, infection

7. Patients who are not suitable for turning and cannot tolerate the side-lyingposition.

8. Patients with known allergies or keloid scarring

9. Women who are known to be pregnant or breastfeeding or who are planning to have ababy during the study period.

10. Patients who have participated in a clinical trial of another drug or medical devicewithin 3 months.

11. Patients who, in the opinion of the investigator, are not suitable for participationin this clinical trial.